Nuance gains territorial rights to Celleron candidates

Celleron Therapeutics Ltd. (Abingdon, U.K.) granted Nuance Biotech Inc. (Shanghai, China) an exclusive option for development and commercialization rights to oncology candidates CXD101 and CXD201 in Greater China and South Africa.

CXD101 is an oral epigenetic immunotherapy in development to treat lymphoma and hepatocellular carcinoma (HCC). CXD201 is an oral topoisomerase I ( TOP1) inhibitor to treat colorectal cancer. Celleron described both candidates as Phase II-ready, and said each is being developed with a companion diagnostic. Neither partner responded to inquiries. ...